1
|
Vizier R, Garnier AR, Dias A, Moreau M, Claron M, Collin B, Denat F, Bellaye PS, Goncalves V. SPECT Imaging of Lysyl Oxidase-like 2 in a Model of Idiopathic Pulmonary Fibrosis. Mol Pharm 2023. [PMID: 37307296 DOI: 10.1021/acs.molpharmaceut.3c00232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Noninvasive imaging of idiopathic pulmonary fibrosis (IPF) remains a challenge. The aim of this study was to develop an antibody-based radiotracer targeting Lysyl Oxidase-like 2 (LOXL2), an enzyme involved in the fibrogenesis process, for SPECT/CT imaging of pulmonary fibrosis. The bifunctional chelator DOTAGA-PEG4-NH2 was chemoenzymatically conjugated to the murine antibody AB0023 using microbial transglutaminase, resulting in a degree of labeling (number of chelators per antibody) of 2.3. Biolayer interferometry confirmed that the binding affinity of DOTAGA-AB0023 to LOXL2 was preserved with a dissociation constant of 2.45 ± 0.04 nM. DOTAGA-AB0023 was then labeled with 111In and in vivo experiments were carried out in a mice model of progressive pulmonary fibrosis induced by intratracheal administration of bleomycin. [111In]In-DOTAGA-AB0023 was injected in three groups of mice (control, fibrotic, and treated with nintedanib). SPECT/CT images were recorded over 4 days p.i. and an ex vivo biodistribution study was performed by gamma counting. A significant accumulation of the tracer in the lungs of the fibrotic mice was observed at D18 post-bleomycin. Interestingly, the tracer uptake was found selectively upregulated in fibrotic lesions observed on CT scans. Images of mice that received the antifibrotic drug nintedanib from D8 up to D18 showed a decrease in [111In]In-DOTAGA-AB0023 lung uptake associated with a decrease in pulmonary fibrosis measured by CT scan. In conclusion, we report the first radioimmunotracer targeting the protein LOXL2 for nuclear imaging of IPF. The tracer showed promising results in a preclinical model of bleomycin-induced pulmonary fibrosis, with high lung uptake in fibrotic areas, and accounted for the antifibrotic activity of nintedanib.
Collapse
Affiliation(s)
- Romane Vizier
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université de Bourgogne, 9 Avenue Alain Savary, 21078 Dijon Cedex, France
| | - Anaïs-Rachel Garnier
- Centre Georges François Leclerc, Service de Médecine Nucléaire, Plateforme d'Imagerie et de Radiothérapie Précliniques, 1 rue du Professeur Marion, 21079 Dijon Cedex, France
| | - Alexandre Dias
- Centre Georges François Leclerc, Service de Médecine Nucléaire, Plateforme d'Imagerie et de Radiothérapie Précliniques, 1 rue du Professeur Marion, 21079 Dijon Cedex, France
| | - Mathieu Moreau
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université de Bourgogne, 9 Avenue Alain Savary, 21078 Dijon Cedex, France
| | - Michael Claron
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université de Bourgogne, 9 Avenue Alain Savary, 21078 Dijon Cedex, France
| | - Bertrand Collin
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université de Bourgogne, 9 Avenue Alain Savary, 21078 Dijon Cedex, France
- Centre Georges François Leclerc, Service de Médecine Nucléaire, Plateforme d'Imagerie et de Radiothérapie Précliniques, 1 rue du Professeur Marion, 21079 Dijon Cedex, France
| | - Franck Denat
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université de Bourgogne, 9 Avenue Alain Savary, 21078 Dijon Cedex, France
| | - Pierre-Simon Bellaye
- Centre Georges François Leclerc, Service de Médecine Nucléaire, Plateforme d'Imagerie et de Radiothérapie Précliniques, 1 rue du Professeur Marion, 21079 Dijon Cedex, France
| | - Victor Goncalves
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université de Bourgogne, 9 Avenue Alain Savary, 21078 Dijon Cedex, France
| |
Collapse
|
2
|
Suzuki H, Muramatsu S, Ichinohe K, Uchimura M, Araki M, Uehara T, Arano Y. Stability Estimation of Gallium Complexes of DOTA Derivatives for Radiotheranostic Applications. ACS OMEGA 2022; 7:43321-43328. [PMID: 36467905 PMCID: PMC9713862 DOI: 10.1021/acsomega.2c06814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/22/2022] [Accepted: 11/07/2022] [Indexed: 06/17/2023]
Abstract
1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid (DO3A) has been used to prepare 68Ga-labeled probes for the diagnostic counterpart of radiotheranostic applications. While DO3A provides stable complexes with therapeutic radionuclides such as 90Y, 177Lu, and 225Ac, further improvement of the in vivo stability of the Ga-DO3A complex is required. Considering the high stability of an intact Ga-DOTA complex, the stability of Ga complexes of DOTA and DO3A derivatives, including benzyl-DOTA (Bn-DOTA), was evaluated to gain fundamental knowledge for developing the next-generation radiotheranostic probes using 68Ga as a diagnostic counterpart. Following the complexation reaction to prepare 67Ga-labeled DOTA and DO3A derivatives, the stability of the resulting 67Ga-labeled compounds was evaluated in murine plasma and apo-transferrin challenge. [67Ga]Ga-Bn-DOTA produced two isomers, and one of the isomers exhibited the highest stability among the tested complexes. The X-ray crystallography showed that the less stable isomer of Ga-Bn-DOTA suggested an N3O3 coordination geometry, while Ga-DOTA and Ga-Bn-DO3A show N4O2 coordination. To further evaluate the stability, a synthetic somatostatin analogue, [Tyr3]octreotide (TOC), was used as a model peptide, and p-COOH-Bn-DOTA and DO3A were conjugated with TOC to prepare DOTA-Bn-TOC and DOTATOC. [67Ga]Ga-DOTA-Bn-TOC also yielded two isomers with varying stability, and one isomer exhibited significantly higher stability than [67Ga]Ga-DOTATOC both in vitro and in vivo. These findings indicate that para-substituted Bn-DOTA would constitute a suitable chelating agent for developing next-generation radiotheranostic probes, although high-performance liquid chromatography purification is needed. Thus, further chemical modification on the Bn-DOTA molecule is also needed to avoid the formation of a Ga complex with the N3O3 configuration.
Collapse
|
3
|
Sales ZS, Mani N, Herrmann AT. Practical syntheses of DOTAGA-DBCO and DFO-DBCO, strained alkyne pre-cursors to radioimmunoconjugates for targeted alpha therapy. Bioorg Med Chem 2022; 73:117010. [PMID: 36126444 DOI: 10.1016/j.bmc.2022.117010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 09/06/2022] [Accepted: 09/09/2022] [Indexed: 11/02/2022]
Abstract
We describe practical methods to prepare DOTAGA-DBCO and DFO-DBCO from commercially available starting materials. DOTAGA-DBCO is available in five steps from cyclen with a 33 % overall yield at gram scale. Our synthesis of DFO-DBCO also proceeds in five steps from commercially available starting materials. These bifunctional molecules possess chelating functionality for the binding of medically important radiometals and a strained alkyne suitable for Huisgen cyclization with an azide. These syntheses represent an important step toward improved radioimmunoconjugates for imaging and therapeutic applications.
Collapse
Affiliation(s)
- Zachary S Sales
- Janssen Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States.
| | - Neelakandha Mani
- Janssen Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Aaron T Herrmann
- Janssen Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States
| |
Collapse
|
4
|
In vivo investigation of Gallium-68 and Bismuth-205/206 labeled beta cyclodextrin for targeted alpha therapy of prostaglandin E2 receptor-expressing tumors in mice. Int J Pharm 2022; 625:122132. [PMID: 36028082 DOI: 10.1016/j.ijpharm.2022.122132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 07/26/2022] [Accepted: 08/18/2022] [Indexed: 11/23/2022]
Abstract
Prostaglandin E2 (PGE2) molecule and its receptors play an important role in the development of malignancies and metastases therefore PGE2 may play a crucial role in the diagnosis and a new therapeutic target in the field of radionuclide therapy of PGE2-positive tumors. PGE2 form complexes with RAMEB (randomly-methylated-beta-cyclodextrin) with high affinity therefore the aim of this present study was to synthesize a PGE2-specific DOTAGA-RAMEB, which can be labeled with diagnostic and therapeutic isotopes also and binds to PGE2-positive tumors. DOTAGA-RAMEB was labeled with 68Ga and 205/206Bi radionuclides and their radiochemical purity (RCP%), partition coefficient (logP values), and in vitro and in vivo stability were determined. For the assessment of the biological properties and the PGE2 specificity of [68Ga]Ga-DOTAGA-RAMEB and [205/206Bi]Bi-DOTAGA-RAMEB in vivo PET imaging and ex vivo biodistribution studies were performed using healthy control and PGE2-positive BxPC-3 tumor-bearing CB17 SCID mice. The RCP% of the newly synthesized [68Ga]Ga-DOTAGA-RAMEB and [205/206Bi]Bi-DOTAGA-RAMEB was higher than 98 %. In vivo studies showed that the tumor-to-background ratio of [68Ga]Ga-DOTAGA-RAMEB was 2.5 ± 0.2 as a result BxPC-3 tumors were clearly identified on PET images. Beside this the ex vivo biodistribution studies showed that the accumulation rate of [68Ga]Ga-DOTAGA-RAMEB and [205/206Bi]Bi-DOTAGA-RAMEB was similar in the PGE2-positive BxPC-3 tumors.
Collapse
|
5
|
McDonagh AW, McNeil BL, Rousseau J, Roberts RJ, Merkens H, Yang H, Bénard F, Ramogida CF. Development of a multi faceted platform containing a tetrazine, fluorophore and chelator: synthesis, characterization, radiolabeling, and immuno-SPECT imaging. EJNMMI Radiopharm Chem 2022; 7:12. [PMID: 35666363 PMCID: PMC9170845 DOI: 10.1186/s41181-022-00164-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Accepted: 05/23/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Combining optical (fluorescence) imaging with nuclear imaging has the potential to offer a powerful tool in personal health care, where nuclear imaging offers in vivo functional whole-body visualization, and the fluorescence modality may be used for image-guided tumor resection. Varying chemical strategies have been exploited to fuse both modalities into one molecular entity. When radiometals are employed in nuclear imaging, a chelator is typically inserted into the molecule to facilitate radiolabeling; the availability of the chelator further expands the potential use of these platforms for targeted radionuclide therapy if a therapeutic radiometal is employed. Herein, a novel mixed modality scaffold which contains a tetrazine (Tz)--for biomolecule conjugation, fluorophore-for optical imaging, and chelator-for radiometal incorporation, in one construct is presented. The novel platform was characterized for its fluorescence properties, radiolabeled with single-photon emission computed tomography (SPECT) isotope indium-111 (111In3+) and therapeutic alpha emitter actinium-225 (225Ac3+). Both radiolabels were conjugated in vitro to trans-cyclooctene (TCO)-modified trastuzumab; biodistribution and immuno-SPECT imaging of the former conjugate was assessed. RESULTS Key to the success of the platform synthesis was incorporation of a 4,4'-dicyano-BODIPY fluorophore. The route gives access to an advanced intermediate where final chelator-incorporated compounds can be easily accessed in one step prior to radiolabeling or biomolecule conjugation. The DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) conjugate was prepared, displayed good fluorescence properties, and was successfully radiolabeled with 111In & 225Ac in high radiochemical yield. Both complexes were then separately conjugated in vitro to TCO modified trastuzumab through an inverse electron demand Diels-Alder (IEDDA) reaction with the Tz. Pilot small animal in vivo immuno-SPECT imaging with [111In]In-DO3A-BODIPY-Tz-TCO-trastuzumab was also conducted and exhibited high tumor uptake (21.2 ± 5.6%ID/g 6 days post-injection) with low uptake in non-target tissues. CONCLUSIONS The novel platform shows promise as a multi-modal probe for theranostic applications. In particular, access to an advanced synthetic intermediate where tailored chelators can be incorporated in the last step of synthesis expands the potential use of the scaffold to other radiometals. Future studies including validation of ex vivo fluorescence imaging and exploiting the pre-targeting approach available through the IEDDA reaction are warranted.
Collapse
Affiliation(s)
- Anthony W McDonagh
- Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada
| | - Brooke L McNeil
- Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.,Life Sciences Division, TRIUMF, Vancouver, BC, V6T 2A3, Canada
| | - Julie Rousseau
- Department of Molecular Oncology, BC Cancer, Vancouver, BC, V5Z 1L3, Canada
| | - Ryan J Roberts
- Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada
| | - Helen Merkens
- Department of Molecular Oncology, BC Cancer, Vancouver, BC, V5Z 1L3, Canada
| | - Hua Yang
- Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.,Life Sciences Division, TRIUMF, Vancouver, BC, V6T 2A3, Canada
| | - François Bénard
- Department of Molecular Oncology, BC Cancer, Vancouver, BC, V5Z 1L3, Canada
| | - Caterina F Ramogida
- Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada. .,Life Sciences Division, TRIUMF, Vancouver, BC, V6T 2A3, Canada.
| |
Collapse
|
6
|
Nakata N, Kobashi N, Okumura Y, Sato M, Matono M, Otsuki K, Tanaka A, Hayashi A. Radiation dosimetry and efficacy of an 89Zr/ 225Ac-labeled humanized anti-MUC5AC antibody. Nucl Med Biol 2022; 108-109:33-43. [PMID: 35276446 DOI: 10.1016/j.nucmedbio.2022.02.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 02/21/2022] [Accepted: 02/22/2022] [Indexed: 12/24/2022]
Abstract
INTRODUCTION Theranostic applications are currently difficult to achieve owing to the limited evaluation of suitable chelators for therapeutic nuclides, such as 225Ac and 227Th. With a focus on targeted α therapy and theranostics using human IgG as a drug-delivery system (i.e., combining highly cytotoxic α-particle emitter radiation with efficient tumor targeting), we developed a recombinant humanized Nd2 (hNd2) as an anti-MUC5AC antibody since MUC5AC is highly expressed in patients with pancreatic cancer. Therefore, we aimed to evaluate the performance of 89Zr- (for diagnosis) and 225Ac- (for therapy) labeling of these antibodies using well-controlled radioisotope (RI)-labeling technology in pancreatic cancer mouse models. METHODS 89Zr-labeled hNd2 (NMK89) and 225Ac-labeled hNd2 (NMT25) were manufactured by chemical conjugation using affinity peptides. A binding assay and the evaluation of plasma stability were performed in vitro to confirm the properties of NMK89 and NMT25. In vivo, we evaluated biodistribution, positron emission tomography (PET)/computed tomography (CT) imaging, antitumor effects, and toxicity. Moreover, the exposure dose in humans was estimated based on the biodistribution evaluation in normal mice. RESULTS NMK89 and NMT25 showed binding specificity to MUC5AC and stability with radiochemical purity ≥90% in mice and human plasma following incubation for 168 h. NMK89 showed high accumulation in tumors and low non-specific accumulation in normal tissues. The antitumor effect of NMT25 was dose-dependent and significantly suppressed tumor growth in the NMT25 treatment groups compared with the control group (p < 0.05). NMK89 and NMT25 showed similar pharmacokinetics and biodistribution characteristics. Additionally, the human estimated exposure dose of NMK89 and NMT25 was confirmed, and the effective dose of NMK89 and NMT25 was 0.33 mSv/MBq and 177.5 mSv/MBq, respectively. CONCLUSION NMK89 showed specific accumulation in the MUC5AC-expressing tumors, while NMT25 showed strong antitumor effects. These results suggest NMK89 and NMT25 as promising theranostic agents for pancreatic cancer.
Collapse
Affiliation(s)
- Norihito Nakata
- Research Center, Nihon Medi-Physics Co., Ltd., 299-0266 Sodegaura, Japan.
| | - Nobuya Kobashi
- Business Development and Project Department, Nihon Medi-Physics Co., Ltd., 136-0075 Tokyo, Japan
| | - Yuki Okumura
- Research Center, Nihon Medi-Physics Co., Ltd., 299-0266 Sodegaura, Japan
| | - Mikiko Sato
- Research Center, Nihon Medi-Physics Co., Ltd., 299-0266 Sodegaura, Japan
| | - Mitsuhiro Matono
- Technology Research & Development Division, Sumitomo Dainippon Pharma Co., Ltd., 564-0053 Osaka, Japan
| | - Kumiko Otsuki
- Technology Research & Development Division, Sumitomo Dainippon Pharma Co., Ltd., 564-0053 Osaka, Japan
| | - Akihiro Tanaka
- Research Center, Nihon Medi-Physics Co., Ltd., 299-0266 Sodegaura, Japan
| | - Akio Hayashi
- Research Center, Nihon Medi-Physics Co., Ltd., 299-0266 Sodegaura, Japan
| |
Collapse
|
7
|
Baek AR, Kim HK, Kim S, Yang JU, Kang MK, Lee JJ, Sung B, Lee H, Kim M, Cho AE, Park JA, Chang Y. Effect of Structural Fine-Tuning on Chelate Stability and Liver Uptake of Anionic MRI Contrast Agents. J Med Chem 2022; 65:6313-6324. [PMID: 35418226 DOI: 10.1021/acs.jmedchem.2c00291] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The purpose of this study is to assess the physicochemical properties and MRI diagnostic efficacy of two newly synthesized 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-type Gd chelates, Gd-SucL and Gd-GluL, with an asymmetric α-substituted pendant arm as potential hepatocyte-specific magnetic resonance imaging contrast agents (MRI CAs). Our findings show that fine conformational changes in the chelating arm affect the in vivo pharmacokinetic behavior of the MRI CA, and that a six-membered chelating substituent of Gd-SucL is more advantageous in this system to avoid unwanted interactions with endogenous species. Gd-SucL exhibited a general DOTA-like chelate stability trend, indicating that all chelating arms retain coordination bonding. Finally, the in vivo diagnostic efficacy of highly stable Gd-SucL as a potential hepatocyte-specific MRI CA was evaluated using T1-weighted MR imaging on an orthotopic hepatocarcinoma model.
Collapse
Affiliation(s)
- Ah Rum Baek
- Institute of Biomedical Engineering Research, Kyungpook National University, 41405 Daegu, Korea
| | - Hee-Kyung Kim
- Preclinical Research Center, Daegu-Gyeongbuk Medical Innovation Foundation, 41061 Daegu, Korea
| | - Soyeon Kim
- Division of RI-Convergence Research, Korea Institute of Radiological and Medical Sciences, 139-706 Seoul, Korea
| | - Ji-Ung Yang
- Division of RI-Convergence Research, Korea Institute of Radiological and Medical Sciences, 139-706 Seoul, Korea
| | - Min-Kyoung Kang
- Laboratory Animal Center, KBIO Osong Medical Innovation Foundation, 28160 Osong, Korea
| | - Jae Jun Lee
- Laboratory Animal Center, KBIO Osong Medical Innovation Foundation, 28160 Osong, Korea
| | - Bokyung Sung
- Department of Medical & Biological Engineering, Kyungpook National University, 41944 Daegu, Korea
| | - Hyeji Lee
- Department of Biomedical Science, Kyungpook National University, 419944 Daegu, Korea
| | - Minsup Kim
- InCerebro Drug Discovery Institute, 01811 Seoul, Korea
| | - Art E Cho
- InCerebro Drug Discovery Institute, 01811 Seoul, Korea
| | - Ji-Ae Park
- Division of RI-Convergence Research, Korea Institute of Radiological and Medical Sciences, 139-706 Seoul, Korea
| | - Yongmin Chang
- Institute of Biomedical Engineering Research, Kyungpook National University, 41405 Daegu, Korea.,Department of Medical & Biological Engineering, Kyungpook National University, 41944 Daegu, Korea.,Department of Biomedical Science, Kyungpook National University, 419944 Daegu, Korea.,Department of Radiology, Kyungpook National University Hospital, 41944 Daegu, Korea.,Department of Molecular Medicine, School of Medicine, Kyungpook National University, 41944 Daegu, Korea
| |
Collapse
|
8
|
Feasibility study and direct extraction of endogenous free metallic cations combining hemodialysis and chelating polymer. Sci Rep 2021; 11:19948. [PMID: 34620952 PMCID: PMC8497614 DOI: 10.1038/s41598-021-99462-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Accepted: 09/21/2021] [Indexed: 11/29/2022] Open
Abstract
In this article, we report the conception and the use of dialysis-based medical device for the extraction of metals. The medical device is obtained by addition in the dialysate of a functionalized chitosan that can chelate endogenous metals like iron or copper. This water-soluble functionalized chitosan is obtained after controlled reacetylation and grafting of DOTAGA. Due to the high mass of chitosan, the polymer cannot cross through the membrane and the metals are trapped in the dialysate during hemodialysis. Copper extraction has been evaluated in vitro using an hemodialysis protocol. Feasibility study has been performed on healthy sheep showing no acute toxicity througout the entire dialysis procedure and first insights of metallic extraction even on healthy animals.
Collapse
|
9
|
Notni J. PSMA-Targeted Therapeutics: A Tale About Law and Economics. J Nucl Med 2021; 62:1482. [PMID: 33789934 DOI: 10.2967/jnumed.121.262308] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Revised: 03/13/2021] [Accepted: 03/16/2021] [Indexed: 11/16/2022] Open
Affiliation(s)
- Johannes Notni
- Institute of Pathology, Technische Universität München, Germany
| |
Collapse
|
10
|
Lee CH, Lim I, Woo SK, Kim KI, Lee KC, Song K, Choi CW, Lim SM. The Feasibility of 64Cu-PSMA I&T PET for Prostate Cancer. Cancer Biother Radiopharm 2021; 37:417-423. [DOI: 10.1089/cbr.2020.4189] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Affiliation(s)
- Chul-Hee Lee
- Department of Nuclear Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
- Division of Applied RI, Research Institute of Radiological & Medical Sciences, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
- Department of Urology, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
| | - Ilhan Lim
- Department of Nuclear Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
| | - Sang-Keun Woo
- Department of Nuclear Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
- Department of Nuclear Medicine, Seoul. National University Hospital, Seoul, Republic of Korea
| | - Kwang Il Kim
- Department of Nuclear Medicine, Seoul. National University Hospital, Seoul, Republic of Korea
| | - Kyo Chul Lee
- Department of Nuclear Medicine, Seoul. National University Hospital, Seoul, Republic of Korea
| | - Kanghyon Song
- Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
| | - Chang Woon Choi
- Department of Nuclear Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
| | - Sang Moo Lim
- Department of Nuclear Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
| |
Collapse
|
11
|
Bhardwaj R, Wolterbeek HT, Denkova AG, Serra-Crespo P. Solid phase extraction-based separation of the nuclear isomers 177mLu and 177Lu. Appl Radiat Isot 2020; 164:109264. [DOI: 10.1016/j.apradiso.2020.109264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 04/21/2020] [Accepted: 06/01/2020] [Indexed: 10/24/2022]
|
12
|
Bodio E, Denat F, Goze C. BODIPYS and aza-BODIPY derivatives as promising fluorophores for in vivo molecular imaging and theranostic applications. J PORPHYR PHTHALOCYA 2020. [DOI: 10.1142/s1088424619501268] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Since their discovery in 1968, the BODIPYs dyes (4,4-difluoro-4-bora-3a, 4a diaza-s-indacene) have found an exponentially increasing number of applications in a large variety of scientific fields. In particular, studies reporting bioapplications of BODIPYs have increased dramatically. However, most of the time, only in vitro investigations have been reported. The in vivo potential of BODIPYs and aza-BODIPYs is more recent, but considering the number of in vivo studies with BODIPY and aza-BODIPY which have been reported in the last five years, we can now affirm that this family of fluorophores can be considered important as cyanine dyes for future in vivo and even clinical applications. This review aims to present representative examples of recent in vivo applications of BODIPYs or aza-BODIPYs, and to highlight the potential of these dyes for optical molecular imaging.
Collapse
Affiliation(s)
- Ewen Bodio
- Institut de Chimie Moléculaire de l’Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 Avenue A. Savary, 21078 Dijon Cedex, France
| | - Franck Denat
- Institut de Chimie Moléculaire de l’Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 Avenue A. Savary, 21078 Dijon Cedex, France
| | - Christine Goze
- Institut de Chimie Moléculaire de l’Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 Avenue A. Savary, 21078 Dijon Cedex, France
| |
Collapse
|
13
|
Leygue N, Enel M, Diallo A, Mestre-Voegtlé B, Galaup C, Picard C. Efficient Synthesis of a Family of Bifunctional Chelators Based on the PCTA[12] Macrocycle Suitable for Bioconjugation. European J Org Chem 2019. [DOI: 10.1002/ejoc.201900280] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Nadine Leygue
- SPCMIB; UMR 5068 CNRS-Université Paul Sabatier-Toulouse III; 118 route de Narbonne 31062 Toulouse France
| | - Morgane Enel
- SPCMIB; UMR 5068 CNRS-Université Paul Sabatier-Toulouse III; 118 route de Narbonne 31062 Toulouse France
| | - Abdel Diallo
- SPCMIB; UMR 5068 CNRS-Université Paul Sabatier-Toulouse III; 118 route de Narbonne 31062 Toulouse France
| | - Béatrice Mestre-Voegtlé
- SPCMIB; UMR 5068 CNRS-Université Paul Sabatier-Toulouse III; 118 route de Narbonne 31062 Toulouse France
| | - Chantal Galaup
- SPCMIB; UMR 5068 CNRS-Université Paul Sabatier-Toulouse III; 118 route de Narbonne 31062 Toulouse France
| | - Claude Picard
- SPCMIB; UMR 5068 CNRS-Université Paul Sabatier-Toulouse III; 118 route de Narbonne 31062 Toulouse France
| |
Collapse
|
14
|
Mishiro K, Hanaoka H, Yamaguchi A, Ogawa K. Radiotheranostics with radiolanthanides: Design, development strategies, and medical applications. Coord Chem Rev 2019. [DOI: 10.1016/j.ccr.2018.12.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
15
|
Litau S, Seibold U, Wängler B, Schirrmacher R, Wängler C. iEDDA Conjugation Reaction in Radiometal Labeling of Peptides with 68Ga and 64Cu: Unexpected Findings. ACS OMEGA 2018; 3:14039-14053. [PMID: 30411057 PMCID: PMC6217686 DOI: 10.1021/acsomega.8b01926] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Accepted: 10/15/2018] [Indexed: 05/31/2023]
Abstract
The inverse electron demand Diels-Alder conjugation reaction has gained increasing importance over the past few years for efficient in vivo and ex vivo radiometal labeling of antibodies. However, the application of this very fast reaction type has not been studied for radiolabeling of peptides so far. We show here the synthesis of 3-benzyl-1,2,4,5-tetrazine-comprising ((1,4,7,10-tetraazacyclododecane-4,7,10-triyl)triacetic acid-1-glutaric acid) (DOTA-GA) and ((1,4,7-triazacyclononane-4,7-diyl)diacetic acid-1-glutaric acid) (NODA-GA) chelators and their radiometal labeling with 68Ga3+ and 64Cu2+. The secondary labeling precursors 68Ga-DOTA-GA-Tz, 68Ga-NODA-GA-Tz, and 64Cu-DOTA-GA-Tz were obtained in high radiochemical yields (RCYs) and purities as well as molar activities for further labeling of trans-cyclooctene (TCO)-modified peptides. However, the following reactions of the radiometal-labeled tetrazines with different TCO-comprising model peptide analogs unexpectedly resulted in the formation of a considerable amount of side products (20-55%) which limits the overall achievable RCYs and purities as well as molar activities of the target radiopeptides. Under otherwise identical, nonradioactive reaction conditions, this effect could however not be observed. In contrast, the corresponding one-step radiolabeling protocols provided the target 68Ga-labeled radiopeptides in exceptionally high RCYs and purities of ≥99% and molar activities of 68-72 GBq/μmol starting from activities of 340-358 MBq of 68Ga. Thus, the usefulness of the two-step labeling of TCO-modified peptides with radiometal-labeled chelator-tetrazines seems to be limited.
Collapse
Affiliation(s)
- Shanna Litau
- Department
of Clinical Radiology and Nuclear Medicine, Biomedical
Chemistry and Department of Clinical Radiology and Nuclear Medicine, Molecular
Imaging and Radiochemistry, Medical Faculty
Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany
| | - Uwe Seibold
- Department
of Clinical Radiology and Nuclear Medicine, Biomedical
Chemistry and Department of Clinical Radiology and Nuclear Medicine, Molecular
Imaging and Radiochemistry, Medical Faculty
Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany
| | - Björn Wängler
- Department
of Clinical Radiology and Nuclear Medicine, Biomedical
Chemistry and Department of Clinical Radiology and Nuclear Medicine, Molecular
Imaging and Radiochemistry, Medical Faculty
Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany
| | - Ralf Schirrmacher
- Department
of Oncology, Division of Oncological Imaging, University of Alberta, 11560 University Avenue, Edmonton T6G 1Z2, Alberta, Canada
| | - Carmen Wängler
- Department
of Clinical Radiology and Nuclear Medicine, Biomedical
Chemistry and Department of Clinical Radiology and Nuclear Medicine, Molecular
Imaging and Radiochemistry, Medical Faculty
Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany
| |
Collapse
|
16
|
Bellaye PS, Moreau M, Raguin O, Oudot A, Bernhard C, Vrigneaud JM, Dumont L, Vandroux D, Denat F, Cochet A, Brunotte F, Collin B. Radiolabeled F(ab') 2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models. Clin Transl Oncol 2018; 20:1557-1570. [PMID: 29777377 PMCID: PMC6223717 DOI: 10.1007/s12094-018-1886-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 04/26/2018] [Indexed: 12/14/2022]
Abstract
PURPOSE This study aimed to investigate theranostic strategies in colorectal and skin cancer based on fragments of cetuximab, an anti-EGFR mAb, labeled with radionuclide with imaging and therapeutic properties, 111In and 177Lu, respectively. METHODS We designed F(ab')2-fragments of cetuximab radiolabeled with 111In and 177Lu. 111In-F(ab')2-cetuximab tumor targeting and biodistribution were evaluated by SPECT in BalbC nude mice bearing primary colorectal tumors. The efficacy of 111In-F(ab')2-cetuximab to assess therapy efficacy was performed on BalbC nude mice bearing colorectal tumors receiving 17-DMAG, an HSP90 inhibitor. Therapeutic efficacy of the radioimmunotherapy based on 177Lu-F(ab')2-cetuximab was evaluated in SWISS nude mice bearing A431 tumors. RESULTS Radiolabeling procedure did not change F(ab')2-cetuximab and cetuximab immunoreactivity nor affinity for HER1 in vitro. 111In-DOTAGA-F(ab')2-cetuximab exhibited a peak tumor uptake at 24 h post-injection and showed a high tumor specificity determined by a significant decrease in tumor uptake after the addition of an excess of unlabeled-DOTAGA-F(ab')2-cetuximab. SPECT imaging of 111In-DOTAGA-F(ab')2-cetuximab allowed an accurate evaluation of tumor growth and successfully predicted the decrease in tumor growth induced by 17-DMAG. Finally, 177Lu-DOTAGA-F(ab')2-cetuximab radioimmunotherapy showed a significant reduction of tumor growth at 4 and 8 MBq doses. CONCLUSIONS 111In-DOTAGA-F(ab')2-cetuximab is a reliable and stable tool for specific in vivo tumor targeting and is suitable for therapy efficacy assessment. 177Lu-DOTAGA-F(ab')2-cetuximab is an interesting theranostic tool allowing therapy and imaging.
Collapse
Affiliation(s)
- P-S Bellaye
- Service de médecine nucléaire, Centre Georges-François Leclerc, 1 rue du professeur Marion, 21000, Dijon, France.
| | - M Moreau
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR CNRS 6302, Université de Bourgogne Franche-Comté, 21078, Dijon Cedex, France
| | - O Raguin
- Oncodesign, 21076, Dijon Cedex, France
| | - A Oudot
- Service de médecine nucléaire, Centre Georges-François Leclerc, 1 rue du professeur Marion, 21000, Dijon, France
| | - C Bernhard
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR CNRS 6302, Université de Bourgogne Franche-Comté, 21078, Dijon Cedex, France
| | - J-M Vrigneaud
- Service de médecine nucléaire, Centre Georges-François Leclerc, 1 rue du professeur Marion, 21000, Dijon, France
| | - L Dumont
- NVH Medicinal, 64 rue Sully, 21000, Dijon, France
| | - D Vandroux
- NVH Medicinal, 64 rue Sully, 21000, Dijon, France
| | - F Denat
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR CNRS 6302, Université de Bourgogne Franche-Comté, 21078, Dijon Cedex, France
| | - A Cochet
- Service de médecine nucléaire, Centre Georges-François Leclerc, 1 rue du professeur Marion, 21000, Dijon, France
| | - F Brunotte
- Service de médecine nucléaire, Centre Georges-François Leclerc, 1 rue du professeur Marion, 21000, Dijon, France
| | - B Collin
- Service de médecine nucléaire, Centre Georges-François Leclerc, 1 rue du professeur Marion, 21000, Dijon, France.,Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR CNRS 6302, Université de Bourgogne Franche-Comté, 21078, Dijon Cedex, France
| |
Collapse
|
17
|
|
18
|
Tran VL, Thakare V, Rossetti F, Baudouin A, Ramniceanu G, Doan BT, Mignet N, Comby-Zerbino C, Antoine R, Dugourd P, Boschetti F, Denat F, Louis C, Roux S, Doussineau T, Tillement O, Lux F. One-pot direct synthesis for multifunctional ultrasmall hybrid silica nanoparticles. J Mater Chem B 2018; 6:4821-4834. [DOI: 10.1039/c8tb00195b] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
A novel and simple route to synthesize ultrasmall silica nanoparticles having hydrodynamic diameters under 10 nm for imaging and therapeutic applications.
Collapse
|
19
|
Heskamp S, Raavé R, Boerman O, Rijpkema M, Goncalves V, Denat F. 89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry. Bioconjug Chem 2017; 28:2211-2223. [PMID: 28767228 PMCID: PMC5609224 DOI: 10.1021/acs.bioconjchem.7b00325] [Citation(s) in RCA: 132] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
![]()
Immuno-positron
emission tomography (immunoPET) with 89Zr-labeled antibodies
has shown great potential in cancer imaging.
It can provide important information about the pharmacokinetics and
tumor-targeting properties of monoclonal antibodies and may help in
anticipating on toxicity. Furthermore, it allows accurate dose planning
for individualized radioimmunotherapy and may aid in patient selection
and early-response monitoring for targeted therapies. The most commonly
used chelator for 89Zr is desferrioxamine (DFO). Preclinical
studies have shown that DFO is not an ideal chelator because the 89Zr–DFO complex is partly unstable in vivo, which results
in the release of 89Zr from the chelator and the subsequent
accumulation of 89Zr in bone. This bone accumulation interferes
with accurate interpretation and quantification of bone uptake on
PET images. Therefore, there is a need for novel chelators that allow
more stable complexation of 89Zr. In this Review, we will
describe the most recent developments in 89Zr radiochemistry,
including novel chelators and site-specific conjugation methods.
Collapse
Affiliation(s)
- Sandra Heskamp
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center , Geert Grooteplein-Zuid 10, 6525 HP Nijmegen, The Netherlands
| | - René Raavé
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center , Geert Grooteplein-Zuid 10, 6525 HP Nijmegen, The Netherlands
| | - Otto Boerman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center , Geert Grooteplein-Zuid 10, 6525 HP Nijmegen, The Netherlands
| | - Mark Rijpkema
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center , Geert Grooteplein-Zuid 10, 6525 HP Nijmegen, The Netherlands
| | - Victor Goncalves
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR6302, CNRS, Université Bourgogne Franche-Comté , F-21000 Dijon, France
| | - Franck Denat
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR6302, CNRS, Université Bourgogne Franche-Comté , F-21000 Dijon, France
| |
Collapse
|
20
|
Chilla SNM, Henoumont C, Elst LV, Muller RN, Laurent S. Importance of DOTA derivatives in bimodal imaging. Isr J Chem 2017. [DOI: 10.1002/ijch.201700024] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
| | - Céline Henoumont
- General Organic and Biomedical chemistry University of Mons; Avenue Victor Maistriau, 19 7000 Mons Belgium
| | - Luce Vander Elst
- General Organic and Biomedical chemistry University of Mons; Avenue Victor Maistriau, 19 7000 Mons Belgium
| | - Robert N. Muller
- General Organic and Biomedical chemistry University of Mons; Avenue Victor Maistriau, 19 7000 Mons Belgium
- Center for Microscopy and Molecular Imaging (CMMI); Institution Rue Adrienne Bolland 8 Gosselies 6041 Belgium
| | - Sophie Laurent
- General Organic and Biomedical chemistry University of Mons; Avenue Victor Maistriau, 19 7000 Mons Belgium
- Center for Microscopy and Molecular Imaging (CMMI); Institution Rue Adrienne Bolland 8 Gosselies 6041 Belgium
| |
Collapse
|
21
|
Rashid HU, Martines MAU, Jorge J, de Moraes PM, Umar MN, Khan K, Rehman HU. Cyclen-based Gd 3+ complexes as MRI contrast agents: Relaxivity enhancement and ligand design. Bioorg Med Chem 2016; 24:5663-5684. [PMID: 27729196 DOI: 10.1016/j.bmc.2016.09.069] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 09/25/2016] [Accepted: 09/28/2016] [Indexed: 12/23/2022]
Abstract
Magnetic Resonance Imaging (MRI) is a noninvasive radiology technique used to examine the internal organs of human body. It is useful for the diagnosis of structural abnormalities in the body. Contrast agents are used to increase the sensitivity of this technique. 1,4,7,10-Tetraazacyclododecane (cyclen) is a macrocyclic tetraamine. Its derivatives act as useful ligands to produce stable complexes with Gd3+ ion. Such chelates are investigated as MRI contrast agents. Free Gd3+ ion is extremely toxic for in vivo use. Upon complexation with a cyclen-based ligand, it is trapped in the preformed central cavity of the ligand resulting in the formation of a highly stable Gd3+-chelate. Better kinetic and thermodynamic stability of cyclen-based MRI contrast agents decrease their potential toxicity for in vivo use. Consequently, such agents have proved to be safest for clinical applications. Relaxivity is the most important parameter used to measure the effectiveness of a contrast agent. A number of factors influence this parameter. This article elucidates detailed strategies to increase relaxivity of cyclen-based MRI contrast agents. 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A) are two key ligands derived from cyclen. They also act as building blocks for the synthesis of novel ligands. A few important methodologies for the synthesis of DOTA and DO3A derivatives are described. Moreover, the coordination geometry of chelates formed by these ligands and their derivatives is discussed as well. Novel ligands can be developed by the appropriate derivatization of DOTA and DO3A. Gd3+-chelates of such ligands prove to be useful MRI contrast agents of enhanced relaxivity, greater stability, better clearance, lesser toxicity and higher water solubility.
Collapse
Affiliation(s)
- Haroon Ur Rashid
- Department of Chemistry, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan; Institute of Chemistry, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil.
| | | | - Juliana Jorge
- Institute of Chemistry, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil
| | - Paula Martin de Moraes
- Institute of Chemistry, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil
| | - Muhammad Naveed Umar
- Department of Chemistry, University of Malakand, Chakdara, Lower Dir, Khyber Pakhtunkhwa, Pakistan
| | - Kamin Khan
- Department of Chemistry, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan
| | - Hanif Ur Rehman
- Department of Chemistry, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan
| |
Collapse
|
22
|
Spang P, Herrmann C, Roesch F. Bifunctional Gallium-68 Chelators: Past, Present, and Future. Semin Nucl Med 2016; 46:373-94. [DOI: 10.1053/j.semnuclmed.2016.04.003] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
23
|
Maindron N, Ipuy M, Bernhard C, Lhenry D, Moreau M, Carme S, Oudot A, Collin B, Vrigneaud JM, Provent P, Brunotte F, Denat F, Goze C. Near-Infrared-Emitting BODIPY-trisDOTA(111) In as a Monomolecular Multifunctional Imaging Probe: From Synthesis to In Vivo Investigations. Chemistry 2016; 22:12670-4. [PMID: 27410465 DOI: 10.1002/chem.201602886] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Indexed: 01/01/2023]
Abstract
A new generation of monomolecular imaging probes (MOMIP) based on a distyryl-BODIPY (BODIPY=boron-dipyrromethene) coupled with three DOTA macrocycles has been prepared (DOTA=1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). The MOMIP presents good fluorescence properties and is very stable in serum. The bimodal probe was conjugated to trastuzumab, and an optical in vivo study showed high accumulation of the imaging agent at the tumor site. (111) In radiometallation of the bioconjugate was performed in high radiochemical yield, highlighting the potential of this new BODIPY-chelators derivative as a bimodal imaging probe.
Collapse
Affiliation(s)
- Nicolas Maindron
- ICMUB UMR CNRS 6302, CNRS, Univ. Bourgogne Franche-Comté, 9, avenue Alain Savary, 21078, Dijon, France
| | - Martin Ipuy
- ICMUB UMR CNRS 6302, CNRS, Univ. Bourgogne Franche-Comté, 9, avenue Alain Savary, 21078, Dijon, France
| | - Claire Bernhard
- ICMUB UMR CNRS 6302, CNRS, Univ. Bourgogne Franche-Comté, 9, avenue Alain Savary, 21078, Dijon, France
| | - Damien Lhenry
- ICMUB UMR CNRS 6302, CNRS, Univ. Bourgogne Franche-Comté, 9, avenue Alain Savary, 21078, Dijon, France
| | - Mathieu Moreau
- ICMUB UMR CNRS 6302, CNRS, Univ. Bourgogne Franche-Comté, 9, avenue Alain Savary, 21078, Dijon, France
| | - Sabin Carme
- ICMUB UMR CNRS 6302, CNRS, Univ. Bourgogne Franche-Comté, 9, avenue Alain Savary, 21078, Dijon, France
| | - Alexandra Oudot
- Centre Georges François Leclerc, Service de médecine nucléaire, 1 rue Professeur Marion, BP77980, 21079, Dijon Cedex, France
| | - Bertrand Collin
- ICMUB UMR CNRS 6302, CNRS, Univ. Bourgogne Franche-Comté, 9, avenue Alain Savary, 21078, Dijon, France.,Centre Georges François Leclerc, Service de médecine nucléaire, 1 rue Professeur Marion, BP77980, 21079, Dijon Cedex, France
| | - Jean-Marc Vrigneaud
- Centre Georges François Leclerc, Service de médecine nucléaire, 1 rue Professeur Marion, BP77980, 21079, Dijon Cedex, France
| | - Peggy Provent
- Oncodesign, 20 rue Jean Mazen, BP27627, 21076, Dijon CEDEX, France
| | - François Brunotte
- Centre Georges François Leclerc, Service de médecine nucléaire, 1 rue Professeur Marion, BP77980, 21079, Dijon Cedex, France
| | - Franck Denat
- ICMUB UMR CNRS 6302, CNRS, Univ. Bourgogne Franche-Comté, 9, avenue Alain Savary, 21078, Dijon, France.
| | - Christine Goze
- ICMUB UMR CNRS 6302, CNRS, Univ. Bourgogne Franche-Comté, 9, avenue Alain Savary, 21078, Dijon, France.
| |
Collapse
|
24
|
Westerlund K, Honarvar H, Norrström E, Strand J, Mitran B, Orlova A, Eriksson Karlström A, Tolmachev V. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. Mol Pharm 2016; 13:1668-78. [PMID: 27010700 DOI: 10.1021/acs.molpharmaceut.6b00089] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
A promising strategy to enable patient stratification for targeted therapies is to monitor the target expression in a tumor by radionuclide molecular imaging. Affibody molecules (7 kDa) are nonimmunoglobulin scaffold proteins with a 25-fold smaller size than intact antibodies. They have shown an apparent potential as molecular imaging probes both in preclinical and clinical studies. Earlier, we found that hepatic uptake can be reduced by the incorporation of negatively charged purification tags at the N-terminus of Affibody molecules. We hypothesized that liver uptake might similarly be reduced by positioning the chelator at the N-terminus, where the chelator-radionuclide complex will provide negative charges. To test this hypothesis, a second generation synthetic anti-HER2 ZHER2:2891 Affibody molecule was synthesized and labeled with (111)In and (68)Ga using DOTAGA and DOTA chelators. The chelators were manually coupled to the N-terminus of ZHER2:2891 forming an amide bond. Labeling DOTAGA-ZHER2:2891 and DOTA-ZHER2:2891 with (68)Ga and (111)In resulted in stable radioconjugates. The tumor-targeting and biodistribution properties of the (111)In- and (68)Ga-labeled conjugates were compared in SKOV-3 tumor-bearing nude mice at 2 h postinjection. The HER2-specific binding of the radioconjugates was verified both in vitro and in vivo. Using the DOTAGA chelator gave significantly lower radioactivity in liver and blood for both radionuclides. The (111)In-labeled conjugates showed more rapid blood clearance than the (68)Ga-labeled conjugates. The most pronounced influence of the chelators was found when they were labeled with (68)Ga. The DOTAGA chelator gave significantly higher tumor-to-blood (61 ± 6 vs 23 ± 5, p < 0.05) and tumor-to-liver (10.4 ± 0.6 vs 4.5 ± 0.5, p < 0.05) ratios than the DOTA chelator. This study demonstrated that chelators may be used to alter the uptake of Affibody molecules, and most likely other scaffold-based imaging probes, for improvement of imaging contrast.
Collapse
Affiliation(s)
- Kristina Westerlund
- Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, AlbaNova University Center , 106 91 Stockholm, Sweden
| | - Hadis Honarvar
- Institute for Immunology, Genetics and Pathology, Uppsala University , 751 05 Uppsala, Sweden
| | - Emily Norrström
- Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, AlbaNova University Center , 106 91 Stockholm, Sweden
| | - Joanna Strand
- Institute for Immunology, Genetics and Pathology, Uppsala University , 751 05 Uppsala, Sweden
| | - Bogdan Mitran
- Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University , 751 05 Uppsala, Sweden
| | - Anna Orlova
- Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University , 751 05 Uppsala, Sweden
| | - Amelie Eriksson Karlström
- Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, AlbaNova University Center , 106 91 Stockholm, Sweden
| | - Vladimir Tolmachev
- Institute for Immunology, Genetics and Pathology, Uppsala University , 751 05 Uppsala, Sweden
| |
Collapse
|
25
|
Bodio E, Le Gendre P, Denat F, Goze C. Development of Trackable Anticancer Agents Based on Metal Complexes. ADVANCES IN INORGANIC CHEMISTRY 2016. [DOI: 10.1016/bs.adioch.2015.09.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
26
|
Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates. J Biol Inorg Chem 2015; 21:83-99. [DOI: 10.1007/s00775-015-1316-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 11/13/2015] [Indexed: 01/26/2023]
|
27
|
Schottelius M, Wirtz M, Eiber M, Maurer T, Wester HJ. [(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res 2015; 5:68. [PMID: 26608882 PMCID: PMC4659791 DOI: 10.1186/s13550-015-0147-6] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Accepted: 11/17/2015] [Indexed: 11/25/2022] Open
Abstract
Background The relevance of prostate-specific membrane antigen (PSMA) targeting in the clinical management of prostate cancer (PCa) is continually increasing, entailing the development of PSMA-targeted molecular probes. Recently, a first PSMA-targeted theranostic concept has been successfully implemented by [68Ga/177Lu]PSMA-I&T. To further exploit the excellent PSMA-targeting characteristics and in vivo performance of the PSMA-I&T platform, [111In]PSMA-I&T was evaluated as a complementary probe for radioguided surgery and SPECT imaging. Findings Compared to [68Ga/177Lu]PSMA-I&T, [111In]PSMA-I&T showed unchangedly high PSMA-affinity and enhanced internalization into PSMA-expressing LNCaP PCa cells. Biodistribution studies in LNCaP xenograft-bearing mice (1 h p.i.) revealed slightly reduced background accumulation of [111In]PSMA-I&T compared to [177Lu]PSMA-I&T and identical tumor uptake of both compounds, leading to increased tumor/background ratios for [111In]PSMA-I&T. An exemplary patient with metastatic PCa underwent preoperative [68Ga]HBED-CC-PSMA PET/CT (1 h p.i.) and [111In]PSMA-I&T SPECT/CT (4 h p.i.), followed by prostatectomy and radioguided extended pelvic lymphadenectomy (24 h p.i.). In [111In]PSMA-I&T SPECT/CT, the previously identified PCa lesions ([68Ga]HBED-CC-PSMA PET/CT) showed high tracer accumulation and were also detectable using planar scintigraphy. The intraoperative use of a hand-held gamma probe allowed detection and resection of all [111In]PSMA-I&T-accumulating lesions. The presence of PSMA-positive tumor tissue in the resected specimens was confirmed histopathologically and via [111In]PSMA-I&T autoradiography. Conclusions [111In]PSMA-I&T shows efficient PSMA targeting in vitro and in vivo, combined with low background accumulation. In an exemplary PCa patient, [111In]PSMA-I&T was successfully applied for preoperative SPECT/CT visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [111In]PSMA-I&T as a complementary tool to [68Ga/177Lu]PSMA-I&T in the clinical management of prostate cancer.
Collapse
Affiliation(s)
- Margret Schottelius
- Chair for Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meissner-Strasse 3, 85748, Garching, Germany.
| | - Martina Wirtz
- Chair for Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meissner-Strasse 3, 85748, Garching, Germany.
| | - Matthias Eiber
- Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675, Munich, Germany.
| | - Tobias Maurer
- Department of Urology, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675, Munich, Germany.
| | - Hans-Jürgen Wester
- Chair for Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meissner-Strasse 3, 85748, Garching, Germany.
| |
Collapse
|
28
|
Gadolinium(III)-DOTA Complex Functionalized with BODIPY as a Potential Bimodal Contrast Agent for MRI and Optical Imaging. INORGANICS 2015. [DOI: 10.3390/inorganics3040516] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
|
29
|
Roubinet B, Massif C, Moreau M, Boschetti F, Ulrich G, Ziessel R, Renard PY, Romieu A. New 3-(Heteroaryl)-2-iminocoumarin-based Borate Complexes: Synthesis, Photophysical Properties, and Rational Functionalization for Biosensing/Biolabeling Applications. Chemistry 2015; 21:14589-601. [DOI: 10.1002/chem.201502126] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Indexed: 01/26/2023]
|
30
|
Lhenry D, Larrouy M, Bernhard C, Goncalves V, Raguin O, Provent P, Moreau M, Collin B, Oudot A, Vrigneaud JM, Brunotte F, Goze C, Denat F. BODIPY: A Highly Versatile Platform for the Design of Bimodal Imaging Probes. Chemistry 2015. [DOI: 10.1002/chem.201501676] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
31
|
Poty S, Désogère P, Šimeček J, Bernhard C, Goncalves V, Goze C, Boschetti F, Notni J, Wester HJ, Denat F. MA-NOTMP: A Triazacyclononane Trimethylphosphinate Based Bifunctional Chelator for Gallium Radiolabelling of Biomolecules. ChemMedChem 2015; 10:1475-9. [DOI: 10.1002/cmdc.201500198] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2015] [Indexed: 12/20/2022]
|
32
|
Baranyai Z, Reich D, Vágner A, Weineisen M, Tóth I, Wester HJ, Notni J. A shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: one-pot click chemistry trimerisation on the TRAP platform. Dalton Trans 2015; 44:11137-46. [PMID: 25999035 DOI: 10.1039/c5dt00576k] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Due to its 3 carbonic acid groups being available for bioconjugation, the TRAP chelator (1,4,7-triazacyclononane-1,4,7-tris(methylene(2-carboxyethylphosphinic acid))) is chosen for the synthesis of trimeric bioconjugates for radiolabelling. We optimized a protocol for bio-orthogonal TRAP conjugation via Cu(I)-catalyzed Huisgen-cycloaddition of terminal azides and alkynes (CuAAC), including a detailed investigation of kinetic properties of Cu(II)-TRAP complexes. TRAP building blocks for CuAAC, TRAP(alkyne)3 and TRAP(azide)3 were obtained by amide coupling of propargylamine/3-azidopropyl-1-amine, respectively. For Cu(II) complexes of neat and triply amide-functionalized TRAP, the equilibrium properties as well as pseudo-first-order Cu(II)-transchelation, using 10 to 30 eq. of NOTA and EDTA, were studied by UV-spectrophotometry. Dissociation of any Cu(II)-TRAP species was found to be independent on the nature or excess of a competing chelator, confirming a proton-driven two-step mechanism. The respective thermodynamic stability constants (log K(ML): 19.1 and 17.6) and dissociation rates (k: 38 × 10(-6) and 7 × 10(-6) s(-1), 298 K, pH 4) show that the Cu(II) complex of the TRAP-conjugate possesses lower thermodynamic stability but higher kinetic inertness. At pH 2-3, its demetallation with NOTA was complete within several hours/days at room temperature, respectively, enabling facile Cu(II) removal after click coupling by direct addition of NOTA trihydrochloride to the CuAAC reaction mixture. Notwithstanding this, an extrapolated dissociation half life of >100 h at 37 °C and pH 7 confirms the suitability of TRAP-bioconjugates for application in Cu-64 PET (cf. t(1/2)(Cu-64) = 12.7 h). To showcase advantages of the method, TRAP(DUPA-Pep)3, a trimer of the PSMA inhibitor DUPA-Pep, was synthesized using 1 eq. TRAP(alkyne)3, 3.3 eq. DUPA-Pep-azide, 10 eq. Na ascorbate, and 1.2 eq. Cu(II)-acetate. Its PSMA affinity (IC50), determined by the competition assay on LNCaP cells, was 18-times higher than that of the corresponding DOTAGA monomer (IC50: 2 ± 0.1 vs. 36 ± 4 nM), resulting in markedly improved contrast in Ga-68-PET imaging. In conclusion, the kinetic inertness profile of Cu(II)-TRAP conjugates allows for simple Cu(II) removal after click functionalisation by means of transchelation, but also confirms their suitability for Cu-64-PET as demonstrated previously (Dalton Trans., 2012, 41, 13803).
Collapse
Affiliation(s)
- Zsolt Baranyai
- Department of Inorganic and Analytical Chemistry, University of Debrecen, Egyetem tér 1, Debrecen, H-4032, Hungary
| | | | | | | | | | | | | |
Collapse
|
33
|
Cakić N, Gündüz S, Rengarasu R, Angelovski G. Synthetic strategies for preparation of cyclen-based MRI contrast agents. Tetrahedron Lett 2015. [DOI: 10.1016/j.tetlet.2014.12.087] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
34
|
Doulain PE, Decréau R, Racoeur C, Goncalves V, Dubrez L, Bettaieb A, Le Gendre P, Denat F, Paul C, Goze C, Bodio E. Towards the elaboration of new gold-based optical theranostics. Dalton Trans 2015; 44:4874-83. [DOI: 10.1039/c4dt02977a] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Four new red BODIPY–gold(i) theranostic compounds were synthesized.
Collapse
|
35
|
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res 2014; 4:63. [PMID: 26116124 PMCID: PMC4452638 DOI: 10.1186/s13550-014-0063-1] [Citation(s) in RCA: 115] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2014] [Accepted: 11/06/2014] [Indexed: 01/12/2023] Open
Abstract
Background Due to its high expression in prostate cancer, PSMA (prostate-specific membrane antigen) represents an ideal target for both diagnostic imaging and endoradiotherapeutic approaches. Based on a previously published highly specific PSMA ligand ([68Ga]DOTA-FFK(Sub-KuE)), we developed a corresponding metabolically stable 1,4,7,10-tetraazacyclododececane,1-(glutaric acid)-4,7,10-triacetic acid (DOTAGA) construct for theranostic treatment of prostate cancer. Methods All ligands were synthesized by a combined solid phase and solution phase synthesis strategy. The affinity of the natgallium and lutetium complexes to PSMA and the internalization efficiency of the radiotracers were determined on PSMA-expressing LNCaP cells. The 68Ga- and 177Lu-labelled ligands were further investigated for lipophilicity, binding specificity, metabolic stability, as well as biodistribution and μPET in LNCaP-tumour-bearing mice. Results Radiochemical yields for 68Ga (3 nmol, 5.0 M NaCl/2.7 M HEPES (approximately 5/1), pH 3.5 to 4.5, 5 min, 95°C) and 177Lu labelling (0.7 nmol, 0.1 M NH4OAc, pH 5.5, 30 min, 95°C) were almost quantitative, resulting in specific activities of 250 to 300 GBq/μmol for the 68Ga analogues and 38 GBq/μmol for 177Lu complexes. Due to metabolic instability of l-amino acid spacers, d-amino acids were implemented resulting in a metabolically stable DOTAGA ligand. Compared to the DOTA ligand, the DOTAGA derivatives showed higher hydrophilicity (logP = −3.6 ± 0.1 and −3.9 ± 0.1 for 68Ga and 177Lu, respectively) and improved affinity to PSMA resulting in an about twofold increased specific internalization of the 68Ga- and 177Lu-labelled DOTAGA analogue. Especially, [68Ga]DOTAGA-ffk(Sub-KuE) exhibits favourable pharmacokinetics, low unspecific uptake and high tumour accumulation in LNCaP-tumour-bearing mice. Conclusions The pair of diagnostic/therapeutic PSMA-ligands [68Ga/177Lu]DOTAGA-ffk(Sub-KuE) possess remarkable potential for the management of prostate cancer.
Collapse
|
36
|
Le Duc G, Roux S, Paruta-Tuarez A, Dufort S, Brauer E, Marais A, Truillet C, Sancey L, Perriat P, Lux F, Tillement O. Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment. Cancer Nanotechnol 2014; 5:4. [PMID: 26561512 PMCID: PMC4631720 DOI: 10.1186/s12645-014-0004-8] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2014] [Accepted: 05/29/2014] [Indexed: 01/22/2023] Open
Abstract
AGuIX nanoparticles are formed of a polysiloxane network surrounded by gadolinium chelates. They present several characteristics. They are easy to produce, they present very small hydrodynamic diameters (<5 nm) and they are biodegradable through hydrolysis of siloxane bonds. Such degradation was evaluated in diluted conditions at physiological pH by dynamic light scattering and relaxometry. AGuIX nanoparticles are also known as positive contrast agents and efficient radiosensitizers. The aim of this paper is to compare their efficiency for magnetic resonance imaging and radiosensitization to those of the commercial gadolinium based molecular agent: DOTAREM®. An experiment with healthy animals was conducted and the MRI pictures we obtained show a better contrast with the AguIX compared to the DOTAREM® for the same amount of injected gadolinium in the animal. The better contrast obtained after injection of Aguix than DOTAREM® is due to a higher longitudinal relaxivity and a residential time in the blood circulation that is two times higher. A fast and large increase in the contrast is also observed by MRI after an intravenous injection of the AGuIX in 9 L gliosarcoma bearing rats, and a plateau is reached seven minutes after the injection. We established a radiotherapy protocol consisting of an irradiation by microbeam radiation therapy 20 minutes after the injection of a specific quantity of gadolinium. After microbeam radiation therapy, no notable difference in median survival time was observed in the presence or absence of gadolinium chelates (38 and 44 days respectively). In comparison, the median survival time is increased to 102.5 days with AGuIX particles showing their interest in this nanomedicine protocol. This remarkable radiosensitizing effect could be explained by the persistent tumor uptake of the particles, inducing a significant nanoscale dose deposition under irradiation.
Collapse
Affiliation(s)
- Géraldine Le Duc
- ID17 Biomedical Beamline, European Synchrotron Radiation Facility, 6 rue Jules Horowitz, 38000 Grenoble, France
| | - Stéphane Roux
- Institut UTINAM, UMR 6213 UFC-CNRS, Université de Franche-Comté, 16 route de Gray, 25030 Besançon, Cedex France
| | - Amandine Paruta-Tuarez
- Institut Lumière Matière, UMR 5306 Université Lyon 1 - CNRS, Team FENNEC, Université de Lyon, 69622 Villeurbanne, Cedex France
| | - Sandrine Dufort
- Nano-H S.A.S, 2 Place de l'Europe, 38070 Saint Quentin-Fallavier, France
| | - Elke Brauer
- ID17 Biomedical Beamline, European Synchrotron Radiation Facility, 6 rue Jules Horowitz, 38000 Grenoble, France
| | - Arthur Marais
- Institut Lumière Matière, UMR 5306 Université Lyon 1 - CNRS, Team FENNEC, Université de Lyon, 69622 Villeurbanne, Cedex France
| | - Charles Truillet
- Institut Lumière Matière, UMR 5306 Université Lyon 1 - CNRS, Team FENNEC, Université de Lyon, 69622 Villeurbanne, Cedex France
| | - Lucie Sancey
- Institut Lumière Matière, UMR 5306 Université Lyon 1 - CNRS, Team FENNEC, Université de Lyon, 69622 Villeurbanne, Cedex France
| | - Pascal Perriat
- MATEIS, UMR 5510 INSA Lyon - CNRS, INSA Lyon, 69621 Villeurbanne, France
| | - François Lux
- Institut Lumière Matière, UMR 5306 Université Lyon 1 - CNRS, Team FENNEC, Université de Lyon, 69622 Villeurbanne, Cedex France
| | - Olivier Tillement
- Institut Lumière Matière, UMR 5306 Université Lyon 1 - CNRS, Team FENNEC, Université de Lyon, 69622 Villeurbanne, Cedex France
| |
Collapse
|
37
|
Kriemen E, Ruf E, Behrens U, Maison W. Synthesis of 1,4,7,10-Tetra-azacyclododecan-1,4,7,10-tetra-azidoethylacetic Acid (DOTAZA) and Related “Clickable” DOTA Derivatives. Chem Asian J 2014; 9:2197-204. [DOI: 10.1002/asia.201402250] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2014] [Indexed: 01/27/2023]
|
38
|
Bimodal imaging probes for combined PET and OI: recent developments and future directions for hybrid agent development. BIOMED RESEARCH INTERNATIONAL 2014; 2014:153741. [PMID: 24822177 PMCID: PMC4009187 DOI: 10.1155/2014/153741] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Accepted: 03/18/2014] [Indexed: 12/02/2022]
Abstract
Molecular imaging—and especially positron emission tomography (PET)—has gained increasing importance for diagnosis of various diseases and thus experiences an increasing dissemination. Therefore, there is also a growing demand for highly affine PET tracers specifically accumulating and visualizing target structures in the human body. Beyond the development of agents suitable for PET alone, recent tendencies aim at the synthesis of bimodal imaging probes applicable in PET as well as optical imaging (OI), as this combination of modalities can provide clinical advantages. PET, due to the high tissue penetration of the γ-radiation emitted by PET nuclides, allows a quantitative imaging able to identify and visualize tumors and metastases in the whole body. OI on the contrary visualizes photons exhibiting only a limited tissue penetration but enables the identification of tumor margins and infected lymph nodes during surgery without bearing a radiation burden for the surgeon. Thus, there is an emerging interest in bimodal agents for PET and OI in order to exploit the potential of both imaging techniques for the imaging and treatment of tumor diseases. This short review summarizes the available hybrid probes developed for dual PET and OI and discusses future directions for hybrid agent development.
Collapse
|
39
|
Volkova Y, Brizet B, Harvey PD, Denat F, Goze C. High Yield SNAr on 8-Halogenophenyl-BODIPY with Cyclic and Acyclic Polyamines. European J Org Chem 2014. [DOI: 10.1002/ejoc.201301900] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
40
|
Adriaenssens L, Liu Q, Chaux-Picquet F, Tasan S, Picquet M, Denat F, Le Gendre P, Marques F, Fernandes C, Mendes F, Gano L, Campello MPC, Bodio E. Novel Heterobimetallic Radiotheranostic: Preparation, Activity, and Biodistribution. ChemMedChem 2014; 9:1567-73. [DOI: 10.1002/cmdc.201300494] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Indexed: 12/23/2022]
|
41
|
Pazos E, Vázquez ME. Advances in lanthanide-based luminescent peptide probes for monitoring the activity of kinase and phosphatase. Biotechnol J 2013; 9:241-52. [DOI: 10.1002/biot.201300203] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2013] [Revised: 08/27/2013] [Accepted: 09/25/2013] [Indexed: 01/16/2023]
|
42
|
Abstract
Radiometals comprise many useful radioactive isotopes of various metallic elements. When properly harnessed, these have valuable emission properties that can be used for diagnostic imaging techniques, such as single photon emission computed tomography (SPECT, e.g.(67)Ga, (99m)Tc, (111)In, (177)Lu) and positron emission tomography (PET, e.g.(68)Ga, (64)Cu, (44)Sc, (86)Y, (89)Zr), as well as therapeutic applications (e.g.(47)Sc, (114m)In, (177)Lu, (90)Y, (212/213)Bi, (212)Pb, (225)Ac, (186/188)Re). A fundamental critical component of a radiometal-based radiopharmaceutical is the chelator, the ligand system that binds the radiometal ion in a tight stable coordination complex so that it can be properly directed to a desirable molecular target in vivo. This article is a guide for selecting the optimal match between chelator and radiometal for use in these systems. The article briefly introduces a selection of relevant and high impact radiometals, and their potential utility to the fields of radiochemistry, nuclear medicine, and molecular imaging. A description of radiometal-based radiopharmaceuticals is provided, and several key design considerations are discussed. The experimental methods by which chelators are assessed for their suitability with a variety of radiometal ions is explained, and a large selection of the most common and most promising chelators are evaluated and discussed for their potential use with a variety of radiometals. Comprehensive tables have been assembled to provide a convenient and accessible overview of the field of radiometal chelating agents.
Collapse
Affiliation(s)
- Eric W Price
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia, CanadaV6T 1Z1.
| | | |
Collapse
|
43
|
Stasiuk GJ, Long NJ. The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging. Chem Commun (Camb) 2013; 49:2732-46. [PMID: 23392443 DOI: 10.1039/c3cc38507h] [Citation(s) in RCA: 151] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Over the last twenty-five years 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) has made a significant impact on the field of diagnostic imaging. DOTA is not the only metal chelate in use in medical diagnostics, but it is the only one to significantly impact on all of the major imaging modalities Magnetic Resonance (MR), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Fluorescence imaging. This crossover of modalities has been possible due to the versatility of DOTA firstly, to complex a variety of metal ions and secondly, the ease with which it can be modified for different disease states. This has driven research over the last two decades into the chemistry of DOTA and the modification of the substituent pendant arms of this macrocycle to create functional, targeted and dual-modal imaging agents. The primary use of DOTA has been with the lanthanide series of metals, gadolinium for MRI, europium and terbium for fluorescence and neodymium for near infra-red imaging. There are now many research groups dedicated to the use of lanthanides with DOTA although other chelates such as DTPA and NOTA are being increasingly employed. The ease with which DOTA can be conjugated to peptides has given rise to targeted imaging agents seen in the PET, SPECT and radiotherapy fields. These modalities use a variety of radiometals that complex with DOTA, e.g.(64)Cu and (68)Ga which are used in clinical PET scans, (111)In, and (90)Y for SPECT and radiotherapy. In this article, we will demonstrate the remarkable versatility of DOTA, how it has crossed the imaging modality boundaries and how it has been successfully transferred into the clinic.
Collapse
Affiliation(s)
- Graeme J Stasiuk
- Department of Chemistry, Imperial College London, South Kensington Campus, London SW7 2AZ, UK
| | | |
Collapse
|
44
|
Volkova YA, Brizet B, Harvey PD, Averin AD, Goze C, Denat F. BODIPY Dyes Functionalized with Pendant Cyclic and Acyclic Polyamines. European J Org Chem 2013. [DOI: 10.1002/ejoc.201300414] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
45
|
Calce E, Monfregola L, De Luca S. Synthetic Strategy to Prepare DOTA-Based Bifunctional Chelating Agent Ready to Bind Biomolecular Probes. Int J Pept Res Ther 2013. [DOI: 10.1007/s10989-013-9348-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
46
|
|
47
|
Brizet B, Bernhard C, Volkova Y, Rousselin Y, Harvey PD, Goze C, Denat F. Boron functionalization of BODIPY by various alcohols and phenols. Org Biomol Chem 2013; 11:7729-37. [DOI: 10.1039/c3ob41370e] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|